featured
Blood-Based Monitoring Identifies Driver HER2 Mutations in Endocrine-Resistant Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ Precision Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Blood-Based Monitoring Identifies Acquired and Targetable Driver HER2 Mutations in Endocrine-Resistant Metastatic Breast Cancer
NPJ Precis Oncol 2019 Jul 16;[EPub Ahead of Print], AJ Medford, TD Dubash, D Juric, L Spring, A Niemierko, N Vidula, J Peppercorn, S Isakoff, BA Reeves, JA LiCausi, B Wesley, G Malvarosa, M Yuen, BS Wittner, MS Lawrence, AJ Iafrate, L Ellisen, B Moy, M Toner, S Maheswaran, DA Haber, A BardiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.